Trial Profile

IIT2018-26 -Hendifar-NETCx: A Descriptive, Multicenter, Single-arm, Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain

Status: Withdrawn prior to enrolment

Phase of Trial: Phase IV

Latest Information Update: 01 Jan 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Telotristat etiprate (Primary)
Indications Malignant carcinoid syndrome; Neuroendocrine tumours
Focus Pharmacodynamics

Most Recent Events

29 Dec 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
09 Aug 2020 Planned primary completion date changed from 1 Aug 2022 to 1 Nov 2022.
09 Aug 2020 Planned initiation date changed from 1 Jul 2020 to 1 Oct 2020.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com